ArticleTheScientificWorldJournal2014
Antimicrobial susceptibility and genetic characterisation of Burkholderia pseudomallei isolated from Malaysian patients.
Article in TheScientificWorldJournal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Article
- Global Prevalence of Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2025Review
- Article
- Analysis of fine-scale phylogeny of Burkholderia pseudomallei in relation to regional geography and drug susceptibility in Thailand.Scientific reports · 2024Article
- The BALB/c Mouse Model for the Evaluation of Therapies to Treat Infections with AerosolizedAntibiotics (Basel, Switzerland) · 2023Article
- Showing the limitations of available phenotypic assays to detectAccess microbiology · 2023Article
- Effective Therapeutic Options for Melioidosis: Antibiotics versus Phage Therapy.Pathogens (Basel, Switzerland) · 2022Review
- Genotyping of Burkholderia pseudomallei Isolated From Patients in South-Western Coastal Region of India.Current microbiology · 2022Article
- One Health surveillance approaches for melioidosis and glanders: The Malaysian perspective.Frontiers in veterinary science · 2022Review
- Investigation of a combination therapy approach for the treatment of melioidosis.Frontiers in microbiology · 2022Article
- Isolated splenic abscess due to melioidosis in type 1 diabetes mellitus: laboratory diagnosis ofBMJ case reports · 2021Article
- Drug screening to identify compounds to act as co-therapies for the treatment of Burkholderia species.PloS one · 2021Article
- Optical microscopy reveals the dynamic nature of B. pseudomallei morphology during β-lactam antimicrobial susceptibility testing.BMC microbiology · 2020Article
- Human Melioidosis.Clinical microbiology reviews · 2020Review
- Environmental interactions are regulated by temperature in Burkholderia seminalis TC3.4.2R3.Scientific reports · 2019Article
- Observational
- Pan-drug-resistant and biofilm-producing strain ofInternational medical case reports journal · 2019Article
- The relationship between bacterial sources and genotype to the antimicrobial resistance pattern ofVeterinary world · 2018Article
- Melioidosis in Malaysia: Incidence, Clinical Challenges, and Advances in Understanding Pathogenesis.Tropical medicine and infectious disease · 2018Review
- Burkholderia pseudomallei: Challenges for the Clinical Microbiology Laboratory.Journal of clinical microbiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Burkholderia pseudomallei, the causative agent of melioidosis, is intrinsically resistant to many antibiotics. Ceftazidime (CAZ), the synthetic β-lactam, is normally used as the first-line antibiotic therapy for treatment of melioidosis. However, acquired CAZ resistance can develop in vivo during treatment with CAZ, leading to mortality if therapy is not switched to a different antibiotic(s) in a timely manner. In this study, susceptibilities of 81 B. pseudomallei isolates to nine different antimicrobial agents were determined using the disk diffusion method, broth microdilution test and Etest. Highest percentage of susceptibility was demonstrated to CAZ, amoxicillin/clavulanic acid, meropenem, imipenem, and trimethoprim/sulfamethoxazole. Although these drugs demonstrated the highest percentage of susceptibility in B. pseudomallei, the overall results underline the importance of the emergence of resistance in this organism. PCR results showed that, of the 81 B. pseudomallei, six multidrug resistant (MDR) isolates carried bpeB, amrB, and BPSS1119 and penA genes. Genotyping of the isolates using random amplified polymorphic DNA analysis showed six different PCR fingerprinting patterns generated from the six MDR isolates clusters (A) and eight PCR fingerprinting patterns generated for the remaining 75 non-MDR isolates clusters (B).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.